Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms. This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Males and females \>18 years of age
• Clinical presentation of takotsubo cardiomyopathy
• Have capacity to give formal consent
Locations
Other Locations
United Kingdom
University of Edinburgh
RECRUITING
Edinburgh
Contact Information
Primary
Jennifer Ramsay
jramsay5@ed.ac.uk
01316501000
Time Frame
Start Date: 2025-08-08
Estimated Completion Date: 2028-08-09
Participants
Target number of participants: 100
Treatments
Placebo_comparator: Acute cohort - no medication
Participants in this arm will have had a diagnosis of takotsubo cardiomyopathy within the last 3 months and will be randomized to receive no medication.
Active_comparator: Acute cohort - Bisoprolol
Participants in this arm will have had a diagnosis of takotsubo cardiomyopathy within the last 3 months and will be randomized to receive Bisoprolol.
Active_comparator: Acute cohort - Valsartan
Participants in this arm will have had a diagnosis of takotsubo cardiomyopathy within the last 3 months and will be randomized to receive Valsartan.
Active_comparator: Chronic cohort - Sacubitril/Valsartan first
Participants in this arm will have had a diagnosis of takotsubo cardiomyopathy more than 6 months ago. They will be randomised to receive Sacubitril/Valsartan first for a 3 month period then switch onto Dapaglifozin for 3 months with a 1 month wash out period in between.
Active_comparator: Chronic cohort - Dapaglifozin first
Participants in this arm will have had a diagnosis of takotsubo cardiomyopathy more than 6 months ago. They will be randomised to receive Dapaglifozin first for a 3 month period then switch onto Sacubitril/Valsartan for 3 months with a 1 month wash out period in between.
No_intervention: Healthy Volunteers
Healthy volunteers will not receive any intervention.
Related Therapeutic Areas
Sponsors
Leads: University of Edinburgh